UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Does non‐metastatic gastric...
    Ajay, Pranay S.; NeMoyer, Rachel; Goyal, Subir; Switchenko, Jeffery M.; Lin, Yong; Jabbour, Salma K.; Carpizo, Darren R.; Paulos, Chrystal M.; Kennedy, Timothy J.; Shah, Mihir M.

    Journal of surgical oncology, August 2023, Letnik: 128, Številka: 2
    Journal Article

    Background Multimodal treatment strategies with surgery as its centerpiece have been accepted as the standard of care in nonmetastatic cardia gastric cancer (CGC). There remains a lack of consensus regarding the optimal multimodal treatment strategy. Method We queried National Cancer Database from 2004 to 2016 to identify patients with resected nonmetastatic CGC who received perioperative chemotherapy (PEC), postoperative chemoradiation therapy (POCR), or postoperative chemotherapy (POC). A subgroup analysis was performed in optimally treated patients defined as initial chemotherapy within 45 days of diagnosis, resection within 45 days of diagnosis, negative margins, adjuvant chemotherapy within 90 days of resection, and standard radiation dose (45 Gy). Kaplan–Meier, Univariate analysis (UVA), and Multivariable analysis (MVA) were performed. Results We identified 2387 patients. Median survival was 38.8 months in the PEC group, 36 months in the POCR group, and 32.3 months in the POC group (p = 0.1025). On UVA, patients treated with PEC had an association with improved survival (HR, 0.83; p = 0.037) when compared with POC. On MVA, no significant difference was noted in overall survival (OS) between PEC, POCR, and POC, similar to subgroup analysis of optimally treated cohort. Conclusion OS rate in nonmetastatic CGC is not significantly different between patients receiving PEC, POCR, or POC.